StockData
Edwards Lifesciences Corp logo

Edwards Lifesciences Corp (EW) stock

EWNYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 10/3060% above fair value
$105.43−1.68 (-1.57%)

Close on Nov 17, 2026Market cap $60.77BP/E 60.6Yield –

Earnings

Edwards Lifesciences's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 9, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$1.72B
+11.0% on a year earlier
adjusted EPS, Q3 FY2026
$0.80
$0.67 a year earlier
Latest guidance
Issued
Nov 4, 2026 · 6 items

Quarterly results

Revenue and earnings per share from each of Edwards Lifesciences's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 9, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 4, 2026after the close$1.72B+11.0%$0.53$0.80Release
Q2 FY2026ended Jun 30, 2026Jul 23, 2026after the close$1.74B+13.8%$0.42$0.78Release
Q1 FY2026ended Mar 31, 2026Apr 23, 2026after the close$1.65B+17.0%$0.66$0.78Release
Q4 FY2025ended Dec 31, 2025Feb 10, 2026after the close$1.57B+12.9%$0.11$0.58Release
Q3 FY2025ended Sep 30, 2025Oct 30, 2025after the close$1.55B+14.4%$0.50$0.67Release
Q2 FY2025ended Jun 30, 2025Jul 24, 2025after the close$1.53B+10.4%$0.57$0.67Release
Q1 FY2025ended Mar 31, 2025Apr 23, 2025after the close$1.41B-11.9%$0.62$0.64Release
Q4 FY2024ended Dec 31, 2024Feb 11, 2025after the close$1.39B-9.2%$0.58$0.59Release
Q3 FY2024ended Sep 30, 2024Oct 24, 2024after the close$1.35B-8.5%$5.13$0.67Release
Q2 FY2024ended Jun 30, 2024Jul 24, 2024after the close$1.39B-9.4%$0.61$0.70Release
Q1 FY2024ended Mar 31, 2024Apr 25, 2024after the close$1.60B+9.6%$0.58$0.66Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Edwards Lifesciences's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
total salesQ4 FY2026$1.67B – $1.75B–NewNov 4, 2026
adjusted EPSnon-GAAPQ4 FY2026$0.61 – $0.69–NewNov 4, 2026
TAVR constant currency sales growthnon-GAAPFY2026+8% – +9%+9% – +11%LoweredJul 23, 2026
TAVR salesFY2026$4.75B – $5.00B$6.50B – $6.90BLoweredJul 23, 2026
TMTTnon-GAAPFY2026$740.00M – $780.00M–NewFeb 10, 2026
total company sales growthnon-GAAPFY2026+11.5%–NewNov 4, 2026
adjusted gross profit marginnon-GAAPFY202678% – 79%–NewNov 4, 2026
gross profit marginnon-GAAPFY202678% – 79%78% – 79%ReaffirmedJul 23, 2026
operating profit marginnon-GAAPFY202628% – 29%–NewNov 4, 2026
operating profit marginnon-GAAPFY202628% – 29%–NewJul 23, 2026
operating profit marginFY202628% – 29%–NewFeb 10, 2026
adjusted EPSnon-GAAPFY2026$2.97 – $3.05–NewNov 4, 2026
adjusted EPSnon-GAAPFY2026$2.95 – $3.05$2.95 – $3.05ReaffirmedJul 23, 2026
effective tax rate, excluding special itemsnon-GAAPFY202616% – 19%–NewJul 23, 2026
R&D as a percentage of salesFY202617%–NewFeb 10, 2026
R&D expense as a percentage of salesFY202617%17%ReaffirmedJul 23, 2026
TAVR salesFY2026$4.70B – $5.00B–NewApr 23, 2026
TAVR sales growthFY2026+7% – +9%–NewApr 23, 2026
TMTT salesFY2026$740.00M – $780.00M–LoweredApr 23, 2026

Guidance vs results

The last range Edwards Lifesciences gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
Q3 FY2026adjusted EPS$0.71 – $0.77$0.80Above range
Q3 FY2026Revenue$1.63B – $1.71B$1.72BAbove range
Q2 FY2026adjusted EPS$0.70 – $0.76$0.78Above range
Q2 FY2026Revenue$1.66B – $1.74B$1.74BAbove range
Q1 FY2026adjusted EPS$0.70 – $0.76$0.78Above range
Q1 FY2026Revenue$1.55B – $1.63B$1.65BAbove range
FY2025adjusted EPS$2.56 – $2.62$2.56Σ4QWithin range
FY2025Revenue$5.90B – $6.10B$6.06BΣ4QWithin range
FY2025Revenue growth+10%+5.75%Σ4QBelow range
Q4 FY2025adjusted EPS$0.58 – $0.64$0.58Within range
Q4 FY2025Revenue$1.51B – $1.59B$1.57BWithin range
Q3 FY2025adjusted EPS$0.54 – $0.60$0.67Above range

Guidance history

Every forecast Edwards Lifesciences put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 4, 2026adjusted EPSFY2026$2.97 – $3.05New
Nov 4, 2026adjusted EPSQ4 FY2026$0.61 – $0.69New
Nov 4, 2026adjusted gross profit marginFY202678% – 79%New
Nov 4, 2026operating profit marginFY202628% – 29%New
Nov 4, 2026total salesQ4 FY2026$1.67B – $1.75BNew
Nov 4, 2026total company sales growthFY2026+11.5%New
Jul 23, 2026adjusted EPSQ3 FY2026$0.71 – $0.77New
Jul 23, 2026adjusted EPSFY2026$2.95 – $3.05Reaffirmed
Jul 23, 2026gross profit marginFY202678% – 79%Reaffirmed
Jul 23, 2026operating profit marginFY202628% – 29%New
Jul 23, 2026R&D expense as a percentage of salesFY202617%Reaffirmed
Jul 23, 2026effective tax rate, excluding special itemsFY202616% – 19%New
Jul 23, 2026TAVR constant currency sales growthFY2026+8% – +9%Lowered
Jul 23, 2026total salesQ3 FY2026$1.63B – $1.71BNew
Jul 23, 2026TAVR salesFY2026$4.75B – $5.00BLowered
Jul 23, 2026total company salesFY2026$6.60B – $6.90BRaised
Jul 23, 2026TMTT salesFY2026$760.00M – $780.00MLowered
Jul 23, 2026total company constant currency sales growthFY2026+10% – +11%Raised
Apr 23, 2026adjusted EPSQ2 FY2026$0.70 – $0.76New
Apr 23, 2026adjusted EPSFY2026$2.95 – $3.05Raised

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Edwards Lifesciences filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Update
  4. Results
  5. Results
  6. Update
  7. Update
  8. Results
  9. News
  10. Update
  11. Results
  12. Results
  13. Results
  14. Results
  15. Update

See a number that looks wrong?